Our data presented in the current study indicate that a combination therapy of Dabrafenib or Vemurafenib together with reagents that allow RIPK3 reconstitution could be such a strategy that was tested in vitro in melanoma (Figure 6). The gene discussed is RIPK3; the disease is melanoma.